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DOI 10.1016/j.stem.2008.11.001Despite the immature state of stem cell
medicine, patients are seeking and ac-
cessing putative stem cell therapies in
an ‘‘early market’’ in which direct-to-con-
sumer advertising via the internet likely
plays an important role. We analyzed
stem cell clinic websites and appraised
the relevant published clinical evidence
of stem cell therapies to address three
questions about the direct-to-consumer
portrayal of stem cell medicine in this
early market: What sorts of therapies are
being offered? How are they portrayed?
Is there clinical evidence to support the
use of these therapies? We found that
the portrayal of stem cell medicine on pro-
vider websites is optimistic and unsub-
stantiated by peer-reviewed literature.
Few areas of science have generated
as much public interest as stem cell
research. Advances in stem cell medicine
promise novel, cell-based therapies for
many diseases in which conventional
medicine is ineffective (Bongso and
Richards, 2004; Mimeault et al., 2007).
But numerous scientific questions remain
unanswered, and scientists generally do
not recommend these therapies for gen-
eral access (Braude et al., 2005; Coutts
and Keirstead, 2008; Daley et al., 2003;
Lassmann, 2005). Nonetheless, patients
are accessing putative therapies from pri-
vately operated clinics across the world
(Lang, 2007; Bodeen, 2008; Baker, 2005;
Enserink, 2006). Beike Biotech, a Chinese
clinic specializing in neurologic disorders,
claims to have treated over 3000 patients
at its 24 hospital clinics in China (McCul-
lough, 2008). ACT, fromTurks andCaicos,
and Emcell, from Ukraine, claim to have
treated over 700 and over 2000 patients,
respectively (see Table S1 available on-
line). Many of these clinics advertise
directly to patients via the internet. This
mode of communication is an important
means of reaching patients, with 8 million
Americans searching for health informa-tion on the internet on any given day
(Fox, 2006). Indeed, given the uncertain
regulatory status of stem cell therapies,
the internet may be the only means by
which these clinics are able to reach
patients in North America.
To characterize the direct-to-consumer
portrayal of stem cell medicine, we per-
formed a content analysis of websites
obtained by a Google (www.google.com)
search for ‘‘stem cell therapy’’ or ‘‘treat-
ment’’ in August, 2007 (Weare and Lin,
2000; Zhang, 2005). This ‘‘snapshot’’ of
online stem cell clinics returned 19 web-
sites claiming the use of stem cells for
the treatment of disease (detailed search
and analysis procedures are provided in
theSupplemental Data; includedwebsites
are listed in Table S1). In addition to
treating disease, eight (42%) of these sites
treated otherwise healthy patients for
cosmesis (three sites, 16%) or health
enhancement (eight sites, 42%). Impor-
tantly, these clinics self-reported the ad-
ministration of stem cells. Clinics’ uses of
the ‘‘stem cell’’ label were taken at face
value. Despite adopting this label in the
following analysis, we have no knowledge
of the true ‘‘stemness’’ of clinics’ interven-
tions. Indeed, given the heterogeneity of
cell populations and scientists’ limited
abilities to sort them, it is likely that
‘‘stem cell therapies’’ contain numerous
other cells in addition to stem cells, to
the extent that they contain stem cells at
all. This caveat applies equally to thera-
pies promoted to consumers by stem
cell clinics, and to therapies now under in-
vestigation in clinical trials.
What therapies are being offered? Adult
autologous stem cells were most com-
monly provided (9 sites, 47%), followed
by fetal stem cells, cord blood stem cells,
and embryonic stem cells (see Table 1).
Stem cells were most often obtained
from the patient’s bone marrow (7 sites,
37%) and/or peripheral blood (5 sites,Cell Stem Cell 326%), although some sites obtained stem
cells from patient fat, blood or marrow do-
nors, aborted fetuses, patient’s skin, ani-
mal tissues, and human placental tissue.
Treatments were most commonly admin-
istered by infusion into cerebrospinal fluid
(6 sites, 32%). Peripheral intravenous ad-
ministration was common as well (6 sites,
32%). Four sites (21%) obtained access to
deep body cavities. For example, www.
nrrfr.com and www.puhuachina.com
both advertised stem cells transplanted
by injection deep into the brain via craniot-
omy or by injection into the spinal cord
parenchyma via laminectomy. Although
a wide range of treatments are repre-
sented, the most frequently provided
treatment was autologous stem cells
obtained from bone marrow or peripheral
blood reintroduced into the body by
lumbar puncture or IV infusion.
Numerous indications for treatment
were observed, representing diverse cat-
egories ranging from neurologic disease
to allergies (indications are listed in Table
S2). Themost commonly mentioned cate-
gories were neurologic and cardiovascu-
lar disease, mentioned by 16 (84%), and
12 (63%) sites, respectively. Among the
neurologic diseases, multiple sclerosis
(MS), stroke, Parkinson’s disease, spinal
cord injury (SCI), and Alzheimer’s disease
were most common. Cardiovascular indi-
cations were typically ischemic heart dis-
ease related. Seven sites (37%) treated
congenital diseases, mainly cerebral
palsy, autism, and Duchenne muscular
dystrophy. Regarding risks and benefits,
all websites (19, 100%) advertised im-
provement in disease state as a benefit
of therapy. In contrast, most (14, 74%)
sites did not mention particular risks. A
few sites mentioned procedural risks or
other risks, such as nonspecific fever or
tingling.
How are stem cell therapies por-
trayed? This question called for the, December 4, 2008 ª2008 Elsevier Inc. 591
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Stem Cell Type Frequency %
Adult, autologous 9 47
Fetal 6 32
Cord blood 4 21
Embryonic 2 11
Adult, allogeneic 2 11
Adjuncts 0 0
Unspecified 0 0
Stem Cell Source Frequency %
Bone marrow 7 37
Blood or marrow donors 5 26
Peripheral blood 5 26
Fetuses 4 21
Fat 2 11
Unspecified 2 11
Other 3 16
Transplantation Procedure Frequency %
Intrathecal, into the CSF 6 32
Intravenous 6 32
Subcutaneous or intramuscular 4 21
Surgical transplantation 4 21
Catheterization of deep body vessels 3 16
By mouth 1 5
Topical 1 5
We extracted information from each clinic’s website on the stem cell types provided, the source of
these stem cells, and on each clinic’s transplantation procedure. Frequencies do not sum to n = 19
or 100% because several sites fitted into more than one category per concept. Stem cell source is
patient’s own unless otherwise noted. The stem cell type denoted ‘‘fetal’’ was composed of neural
cells, hematopoietic cells, olfactory ensheathing cells, placental cells, and amniotic cells harvested
from aborted fetuses. ‘‘Other’’ stem cell sources include animal sources (shark and sheep) and skin
stem cells.measurement of holistic impressions
about each site’s portrayal of the indica-
tions, risks, benefits, and readiness of the
therapy offered (See Supplemental Re-
sults for examples illustrating each im-
pression). Indications for treatment were
scored for determinacy, i.e., the extent
to which indications were well bounded
and specific, as opposed to open ended
or vague. Indications scored very or
somewhat unclear or indeterminate in
68% of sites (see Figure 1A). The impres-
sion of indeterminacy was typically
generated by the presence of catch-all
categories like aging, ‘‘increased feelings
of energy,’’ and by long lists of diseases
spanning numerous clinical categories.
Indeed, indications on 12 of 19 sites
(63%) spanned 4 or more broad disease
categories.
Portrayals of risks and benefits were
scored for relevance, defined as the592 Cell Stem Cell 3, December 4, 2008 ª20extent to which the risk or benefit is likely
in frequency or dramatic in magnitude
(see Figure 1B). Seventy-nine percent of
websites portrayed benefits as somewhat
or very relevant. In contrast, websites’ risk
portrayals scored as very irrelevant in the
majority (14, 74%) of sites. This asymmet-
ric portrayal of relevance of risks and
benefits contributed to an overall impres-
sion that therapies were safe and effec-
tive. Finally, websites were scored for
the readiness of their therapies for public
access. Ten (53%) sites scored at the
‘‘very’’ positive end of the five point scale
for readiness (see Figure 1C). This
impression was encountered when web-
sites appeared to have accumulated
copious experience with the therapy,
signifying a degree of expertise and
optimization. Sites also established
credibility by advertising the ‘‘latest med-
ical equipment and technology’’ and by08 Elsevier Inc.featuring publications, news articles,
patents, and numerous patient endorse-
ments, giving rise to impressions of read-
iness.
These results demonstrate a general
portrayal of therapy as safe and effective
for a broad range of diseases in the con-
text of routine clinical use. However,
a few websites resisted the general trend.
For example, indications for treatment
with autologous bone-marrow-derived
cells were clear and well bounded in
www.vescell.com. This site only treated
ischemic heart disease refractory to con-
ventional therapy. As another example,
the portrayal of benefits in www.nrrfr.
com was unique. This clinic was guarded
in describing the benefits patients would
obtain. Indeed, reports of unsuccessful
treatment could be found on its site.
We next askedwhether there was peer-
reviewed clinical evidence to support the
use of these therapies in a routine clinical
setting. We performed a PubMed (http://
www.ncbi.nlm.nih.gov) search in July
2008 for primary human studies reporting
the clinical effects of any stem cell thera-
pies for indications mentioned ten or
more times in our top two disease cate-
gories, i.e., neurologic and cardiovascular
diseases. Targeted indications were as
follows: MS, Parkinson’s disease, stroke,
Alzheimer’s disease, and SCI. Heart dis-
easealsoappeared frequently amongpro-
vider websites. However, our search for
evidence related to heart disease was lim-
ited to systematic reviews of RCTs evalu-
ating autologous hematopoietic stem cell
transplantation (AHSCT) for acute myo-
cardial infarction (AMI). Forty-one studies
and four systematic reviews were ap-
praised using evidence-based medicine
(EBM) principles (Sackett et al., 1996;
Guyatt et al., 2008) (see Supplemental
Procedures; Table S3 summarizes the
number of records screened, included,
and excluded; and Tables S4 and S5
contain data extracted fromeach included
study). In describing the current state of
stem cell medicine, we caution against
drawing conclusions about the potential
of stem cell medicine from our
analysis. Our purpose is to evaluate the
direct-to-consumer portrayal of stem cell
medicine.
Studies reporting a range of non-
AHSCT stem cell therapies for spinal
cord injury and stroke were included. For
example, two studies treated stroke with
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CorrespondenceFigure 1. Impressions Conveyed by Websites’ Portrayals of Stem Cell Therapies
(A–C) The following holistic impressions about each site’s portrayal of the indications, risks, benefits, and
readiness of the therapy offered were measured: determinacy of indications (i.e., the extent to which in-
dications were well bounded and specific, as opposed to open-ended or vague), relevance (i.e., the extent
towhich the risk or benefit is likely in frequency or dramatic inmagnitude), and readiness, (i.e., the extent to
which the therapy is ready for general clinical access, as opposed to restricted access in the context of
a trial protocol only). VC, very clear, bounded; SC, somewhat clear, bounded; SI, somewhat unclear,
indeterminate; VI, very unclear, indeterminate.NT2/D1 teratocarcinoma-derived neu-
rons, and five studies treated SCI with
olfactory ensheathing cells. These studies
were generally of small size, low method-
ological quality (e.g., no control group),
and uncertain, negative, or contradictory
findings. AHSCT was employed by sev-
eral studies treating SCI and stroke. Only
one case report reported positive out-
comes from the use of AHSCT for stroke.
Regarding AHSCT for SCI, we found two
unblinded, nonrandomized controlled
trials with 36 and 48 patients. While the
former found higher improvements in
American Spinal Injury Association (ASIA)
scores among treated patients versus
controls, significance was tested within
groups only. The latter did not report con-
trol outcomes. The evidence for stem cell
therapies for SCI and stroke is generally
underdeveloped.We were unable to find any studies of
stem cell therapy for Parkinson’s disease.
Notably, transplantation with fetal mes-
encephalon grafts containing dopamine
neurons has been employed experimen-
tally to treat Parkinson’s disease since the
late 1980s (Freed et al., 1990). These trans-
plants may contain stem cells, and further
trials are now underway (e.g., Clinical-
Trials.gov., 2008). However, the safety of
the therapy is not certain (e.g., Olanow
et al., 2003), and recent opinions suggest
that much optimization work remains
before the treatmentcanberecommended
for clinical use (McKay and Kittappa, 2008;
Suchowersky, 2008;BraakandDel Tredici,
2008;Snyder andOlanow, 2005). Similarly,
we were unable to find a study of stem cell
therapy for Alzheimer’s disease.
Stem cell therapies have had a slightly
longer history with MS. AHSCT for MSCell Stem Cell 3has been employed in trials as early as
1997 (McAllister et al., 1997). Findings
from one large case series suggest that
AHSCT may have a role to play in slowing
the progression of disease (Saccardi
et al., 2006). However, clinical outcomes
are variable and ‘‘not obviously better
than the natural history of patients with
multiple sclerosis’’ (Burt et al., 2007).
This conclusion reflects a preponderance
of noncomparative studies and substan-
tial uncertainty in patient selection and
conditioning techniques. Additionally, the
MS trials included in our review employed
myeloablative conditioning regimens,
commonly the chemotherapy combina-
tion BEAM or total body irradiation, fol-
lowed by cyclophosphamide. In contrast,
immunoablation played no role in any
therapy mentioned by our websites.
Finally, we considered four systematic
reviews with meta-analyses for AHSCT
to treat AMI (see Supplemental Data and
Table S5). Reviewed studies were mostly
RCTs of varying quality. Heterogeneity
notwithstanding, all six reviews reported
a small but statistically significant advan-
tage in change in left ventricular ejection
fraction (LVEF) among treated patients
versus controls, with pooled point esti-
mates among these reviews ranging from
2.88% to 3.46%. All four reviews also
reported no increase in adverse events
related to treatment. Thus, there is evi-
dence that AHSCT for AMI is safe and, to
a limited extent, efficacious. However,
LVEF is a surrogate outcome, andwhether
the observed 2.88% to 3.46% higher
improvement in LVEF leads to meaningful
clinical/functional improvements, like de-
creased mortality, is uncertain.
For stem cell therapies for MS, Parkin-
son’s disease, stroke, Alzheimer’s dis-
ease, and SCI, we consider any treatment
recommendationmade on the basis of the
reviewed evidence to be low grade (see
Phillips et al., 2001). For AMI, evidence of
physiologic improvements exists, but
any treatment recommendation must be
tempered by the limitations of small
treatment effects and the use of physio-
logic outcomes. In any event, only www.
vescell.com offered AHSCT exclusively
for cardiologic indications. Eighty-four
percent of websites advertised therapy
for neurologic indications. We therefore
find that the treatments offered on stem
cell websites are generally unsupported
by the clinical evidence., December 4, 2008 ª2008 Elsevier Inc. 593
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treatments being offered directly to con-
sumers via the internet. Websites gener-
ally portrayed therapies as safe, effective,
and ready for routine use in a wide variety
of conditions. In contrast, the published
clinical evidence is unable to support the
use of these therapies for the routine
treatment of disease. The direct-to-con-
sumer portrayal of stem cell medicine is
optimistic and unsupported by published
evidence.
This finding might suggest that pro-
viders are making inaccurate claims in
their direct-to-consumer promotional ma-
terials. Patients may not be receiving
sufficient and appropriate information
and may be shouldering inordinate risks.
Clinics may also be contributing to public
expectations that exceed what the field
can reasonably achieve. However, this
interpretation is subject to the following
limitations: information available from
websites may not be indicative of the
information actually shared with patients
during their clinical encounters; the ag-
gregate data, collected from a heteroge-
neous group of clinics, cannot be used
to evaluate the claims of any particular
clinic; and finally, we do not test the accu-
racy of websites’ claims directly by ana-
lyzing actual outcome data. We show,
instead, that there is a lack of high quality
evidence supporting stem cell clinics’
claims. Even supposing that clinics have
indeed observed successful recovery
from chronic disease posttreatment, a
lack of good evidence precludes a valid
or precise inference that the observed
improvement is attributable to the inter-
ventions. If, in fact, the interventions were
not effective, then patients would have
been subjected to inappropriate risk and
financial burden. The average cost of
a course of therapy among the four web-
sites that mentioned costs was $21,500,
excluding travel and accommodation for
patients and care givers. And examples
of serious treatment side effects can be
found (Dobkin et al., 2006). In conclusion,
patients should be wary of claims made
by stem cell clinics on the internet. The
direct-to-consumer portrayal of stem cell
medicine is overoptimistic given the594 Cell Stem Cell 3, December 4, 2008 ª20peer-review literature. More research is
needed either to substantiate these
clinics’ claims or to develop stem cell
therapies that actually work.
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